retatrutide phase 2 trial type 2 diabetes results 2024 Retatrutide, a GIP, GLP-1 and glucagon receptor Triple hormone receptor agonist retatrutide

Fast and Effective Bypass the digestive system for instant hydration, energy, and immune support

In a 48-week phase II clinical trial conducted on patients with type 2 diabetes and obesity, treatment with a dose of 10 mg/kg of bimagrumab resulted in a significant reduction in fat mass by 20.5% (compared to 0.5% in the placebo group), while lean body mass increased by 3.6% (as opposed to a decrease of 0.8% in the placebo group), leading to an overall body weight reduction of -6.5%, which was substantially better than the -0.8% observed in the placebo group

D-psicose, an epimer of D-fructose, favorably alters lipid metabolism in Sprague-Dawley rats

The Evidence: "GLP-1 peptide is 100% homologous between cats and humans, making incretin-based therapies physiologically viable for feline patients." This homology is crucial

Track shots, meals, and side effects and make every dose count, from week one to goal weight.